+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drugs for Conn's Syndrome Market - Global Forecast 2025-2030- Product Image
Drugs for Conn's Syndrome Market - Global Forecast 2025-2030- Product Image
Sale

Drugs for Conn's Syndrome Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 181 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6127090
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The mineralocorticoid receptor antagonist (MRA) market for Conn’s syndrome is undergoing significant transformation, presenting dynamic opportunities for stakeholders navigating shifting regulatory frameworks, supply chain pressures, and evolving therapeutic standards. Senior decision-makers operating in this landscape must understand emerging pharmacological innovations, supply chain disruptions, and nuanced regional drivers shaping growth and risk across the ecosystem.

Market Snapshot: Conn’s Syndrome Therapeutics

The global market for mineralocorticoid receptor antagonists in primary aldosteronism (Conn’s syndrome) is marked by rapid evolution in diagnosis and management. The introduction of nonsteroidal MRAs, notable advancements in digital health integration, and shifting reimbursement dynamics have redefined patient care. Market forces, including adaptive regulatory pathways and varied regional adoption rates, have accelerated guideline revisions and competitive repositioning. This environment is characterized by an expanding product pipeline that includes both steroidal and nonsteroidal formulations, each addressing distinct clinical needs across patient populations.

Scope & Segmentation of Mineralocorticoid Receptor Antagonist Market

This report provides comprehensive segmentation and coverage of the global Conn’s syndrome therapeutic market, including key sub-segments, regions, and stakeholders.

  • Drug Classes: Nonsteroidal MRAs such as finerenone; Steroidal MRAs including eplerenone and spironolactone.
  • Therapy Lines: Categorized into first, second, and third or later lines of intervention to reflect evolving evidence and patient stratification practices.
  • Routes of Administration: Oral options for chronic, outpatient use; Intravenous formulations important for acute or perioperative management.
  • Distribution Channels: Hospital and retail pharmacies each play a pivotal role in therapy continuity and patient access.
  • Geographic Coverage: Americas (including detailed coverage for United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio—Canada, Mexico, Brazil, Argentina); Europe, Middle East & Africa (with focus markets such as the UK, Germany, France, Russia, Saudi Arabia, South Africa, among others); Asia-Pacific (China, India, Japan, Australia, South Korea, plus Southeast Asian and Far East markets).
  • Key Companies: Major participants include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., Sandoz International GmbH, Dr. Reddy’s Laboratories Limited, Sun Pharmaceutical Industries Ltd., Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, and Aurobindo Pharma Limited.

Key Takeaways for Senior Leaders

  • Nonsteroidal receptor antagonists are changing treatment algorithms by offering improved selectivity and tolerability, especially in complex patient subgroups.
  • Digital health solutions and remote patient monitoring support disease management and drive value-based care models by generating actionable real-world evidence.
  • Segmentation by therapy line, administration route, and distribution channel enables precise product positioning and aligns with varied patient profiles.
  • Collaborative strategies—across co-development, digital integration, and supply contracts—are central to sustaining competitive enhancements and market expansion.
  • Regional dynamics, including differentiated payer models and resource allocation, shape adoption trends and necessitate tailored market access plans.

Tariff Impact: Supply Chain and Market Access

Recent updates to United States tariff schedules for pharmaceutical ingredients have driven cost realignments throughout the MRA supply chain. Vertical integration and nearshoring are favored, with large manufacturers absorbing supply shocks and smaller firms engaging contract manufacturing partners to ensure continuity. Policy advocacy is active, aiming to ease the regulatory and logistical burden for essential therapies and maintain uninterrupted patient access. Pricing models have been adjusted in response, with tiered frameworks and renegotiated supply agreements becoming more prevalent across markets facing tariff pressures.

Methodology & Data Sources

This analysis synthesizes peer-reviewed research, clinical trials, regulatory documentation, and longitudinal real-world evidence. Primary inputs include structured interviews with endocrinologists, cardiologists, and supply chain specialists globally, complemented by validated sales data and stakeholder perspectives. Quantitative and qualitative data have been rigorously triangulated and independently peer reviewed to maximize accuracy and insight.

Why This Report Matters

  • Enables leadership teams to align portfolio strategy with disruptive trends in Conn’s syndrome pharmacotherapy.
  • Supports informed planning around supply chain risk, regulatory changes, and regional channel optimization.
  • Delivers actionable intelligence for competitive positioning and evidence-driven market expansion.

Conclusion

Stakeholders in Conn’s syndrome therapeutics must balance clinical innovation, operational resilience, and localized execution to remain competitive. This report offers the clarity and guidance required for strategic advancement amid ongoing market transformation.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of next-generation nonsteroidal mineralocorticoid receptor antagonists for primary aldosteronism management
5.2. Expansion of biomarker-driven diagnostic protocols to enhance early Conn’s syndrome detection and treatment selection
5.3. Emerging pipeline of selective aldosterone synthase inhibitors reshaping primary hyperaldosteronism treatment paradigms
5.4. Growing off-label evaluation of finerenone in Conn’s syndrome patients with comorbid kidney and cardiovascular disease
5.5. Real-world evidence on long-term cardiovascular and renal outcomes comparing spironolactone and eplerenone in primary aldosteronism
5.6. Pricing and access pressure on generic spironolactone amid launch of novel branded mineralocorticoid receptor antagonists
5.7. Integration of AI-enabled clinical decision support tools to tailor individualized treatment regimens for Conn’s syndrome
5.8. Regional market acceleration in Asia Pacific driven by expanded Conn’s syndrome screening and awareness initiatives
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Drugs for Conn's Syndrome Market, by Drug Class
8.1. Introduction
8.2. Nonsteroidal Mineralocorticoid Receptor Antagonists
8.2.1. Finerenone
8.3. Steroidal Mineralocorticoid Receptor Antagonists
8.3.1. Eplerenone
8.3.2. Spironolactone
9. Drugs for Conn's Syndrome Market, by Therapy Line
9.1. Introduction
9.2. First Line Therapy
9.3. Second Line Therapy
9.4. Third or Later Therapy
10. Drugs for Conn's Syndrome Market, by Route of Administration
10.1. Introduction
10.2. Intravenous Administration
10.3. Oral Administration
11. Drugs for Conn's Syndrome Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Retail Pharmacy
12. Americas Drugs for Conn's Syndrome Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Drugs for Conn's Syndrome Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Drugs for Conn's Syndrome Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Pfizer Inc.
15.3.2. Teva Pharmaceutical Industries Ltd.
15.3.3. Viatris Inc.
15.3.4. Sandoz International GmbH
15.3.5. Dr. Reddy's Laboratories Limited
15.3.6. Sun Pharmaceutical Industries Ltd.
15.3.7. Cipla Limited
15.3.8. Lupin Limited
15.3.9. Glenmark Pharmaceuticals Limited
15.3.10. Aurobindo Pharma Limited
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. DRUGS FOR CONN'S SYNDROME MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. DRUGS FOR CONN'S SYNDROME MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. DRUGS FOR CONN'S SYNDROME MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. DRUGS FOR CONN'S SYNDROME MARKET: RESEARCHAI
FIGURE 24. DRUGS FOR CONN'S SYNDROME MARKET: RESEARCHSTATISTICS
FIGURE 25. DRUGS FOR CONN'S SYNDROME MARKET: RESEARCHCONTACTS
FIGURE 26. DRUGS FOR CONN'S SYNDROME MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. DRUGS FOR CONN'S SYNDROME MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY FINERENONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY FINERENONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY EPLERENONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY EPLERENONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY SPIRONOLACTONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY SPIRONOLACTONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY FIRST LINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY FIRST LINE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY SECOND LINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY SECOND LINE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THIRD OR LATER THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THIRD OR LATER THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 73. CANADA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 74. CANADA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 75. CANADA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 76. CANADA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 77. CANADA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 78. CANADA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 79. CANADA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 80. CANADA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 81. CANADA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 82. CANADA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 83. CANADA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. CANADA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. MEXICO DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 86. MEXICO DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 87. MEXICO DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 88. MEXICO DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 89. MEXICO DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 90. MEXICO DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 91. MEXICO DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 92. MEXICO DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 93. MEXICO DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 94. MEXICO DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 95. MEXICO DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. MEXICO DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. BRAZIL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 98. BRAZIL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 99. BRAZIL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 100. BRAZIL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 101. BRAZIL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 102. BRAZIL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 103. BRAZIL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 104. BRAZIL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 105. BRAZIL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 106. BRAZIL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 107. BRAZIL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. BRAZIL DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. ARGENTINA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 110. ARGENTINA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 111. ARGENTINA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 112. ARGENTINA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 113. ARGENTINA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 114. ARGENTINA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 115. ARGENTINA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 116. ARGENTINA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 117. ARGENTINA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 118. ARGENTINA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 119. ARGENTINA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. ARGENTINA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 136. UNITED KINGDOM DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 138. UNITED KINGDOM DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 140. UNITED KINGDOM DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 142. UNITED KINGDOM DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 144. UNITED KINGDOM DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. UNITED KINGDOM DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. GERMANY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 148. GERMANY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 149. GERMANY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 150. GERMANY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 151. GERMANY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 152. GERMANY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 153. GERMANY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 154. GERMANY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 155. GERMANY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. GERMANY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. GERMANY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. GERMANY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. FRANCE DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 160. FRANCE DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 161. FRANCE DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 162. FRANCE DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 163. FRANCE DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 164. FRANCE DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 165. FRANCE DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 166. FRANCE DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 167. FRANCE DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 168. FRANCE DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 169. FRANCE DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. FRANCE DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. RUSSIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 172. RUSSIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 173. RUSSIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 174. RUSSIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 175. RUSSIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 176. RUSSIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 177. RUSSIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 178. RUSSIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 179. RUSSIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 180. RUSSIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 181. RUSSIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. RUSSIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. ITALY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 184. ITALY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 185. ITALY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 186. ITALY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 187. ITALY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 188. ITALY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 189. ITALY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 190. ITALY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 191. ITALY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. ITALY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. ITALY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. ITALY DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. SPAIN DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 196. SPAIN DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 197. SPAIN DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 198. SPAIN DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 199. SPAIN DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 200. SPAIN DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 201. SPAIN DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 202. SPAIN DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 203. SPAIN DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 204. SPAIN DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 205. SPAIN DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. SPAIN DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. UNITED ARAB EMIRATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 208. UNITED ARAB EMIRATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. SAUDI ARABIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 220. SAUDI ARABIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 221. SAUDI ARABIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 222. SAUDI ARABIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 224. SAUDI ARABIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 226. SAUDI ARABIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. SAUDI ARABIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. SAUDI ARABIA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. SOUTH AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 232. SOUTH AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 233. SOUTH AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 234. SOUTH AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 236. SOUTH AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 238. SOUTH AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 240. SOUTH AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. SOUTH AFRICA DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. DENMARK DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 244. DENMARK DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 245. DENMARK DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 246. DENMARK DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 247. DENMARK DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 248. DENMARK DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 249. DENMARK DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 250. DENMARK DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 251. DENMARK DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 252. DENMARK DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 253. DENMARK DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. DENMARK DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. NETHERLANDS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 256. NETHERLANDS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 257. NETHERLANDS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 258. NETHERLANDS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 259. NETHERLANDS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 260. NETHERLANDS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 261. NETHERLANDS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 262. NETHERLANDS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 263. NETHERLANDS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 264. NETHERLANDS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 265. NETHERLANDS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. NETHERLANDS DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. QATAR DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 268. QATAR DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 269. QATAR DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 270. QATAR DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 271. QATAR DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 272. QATAR DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 273. QATAR DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 274. QATAR DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 275. QATAR DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. QATAR DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. QATAR DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. QATAR DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. FINLAND DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 280. FINLAND DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 281. FINLAND DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 282. FINLAND DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 283. FINLAND DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 284. FINLAND DRUGS FOR CONN'S SYNDROME MARKET SIZE, BY STER

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Drugs for Conn's Syndrome market report include:
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sandoz International GmbH
  • Dr. Reddy's Laboratories Limited
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Lupin Limited
  • Glenmark Pharmaceuticals Limited
  • Aurobindo Pharma Limited

Related Reports

Hydrolyzed Collagen Market 2024-2028 - Product Image

Hydrolyzed Collagen Market 2024-2028

  • Report
  • 141 Pages
  • Global
From
Adrenogenital Syndrome Treatment Global Market Report 2025 - Product Image

Adrenogenital Syndrome Treatment Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Nonsteroidal MRAs Market - Global Forecast 2025-2030 - Product Image

Nonsteroidal MRAs Market - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Lennox-Gastaut Syndrome Treatment Market - Global Forecast 2025-2030 - Product Image

Lennox-Gastaut Syndrome Treatment Market - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Nephrology Drugs - Global Strategic Business Report - Product Image

Nephrology Drugs - Global Strategic Business Report

  • Report
  • 386 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.